Cefazolin sodium salt

Research use only, not for human use.

Cefazolin sodium is a first-generation cephalosporin antibiotic, useful for the treatment of a number of bacterial infections.

Cefazolin sodium is a first-generation cephalosporin antibiotic, useful for the treatment of a number of bacterial infections.(In Vitro):Cefazolin sodium (0-300 μg/ml; 6 or 24 h) has a direct anti-inflammatory effect on C8-B4 cells stimulated by lipopolysaccharide.Cefazolin sodium (0-400 μM; 72 h) treatment inhibits IL-2, IL-4 and IL-15-induced cell proliferation.Cefazolin sodium (0-400 μM; 30 min) treatment inhibits IL-2, IL-4, IL-15 and IL-21-stimulated JAK3 phosphorylation.(In Vivo):Cefazolin sodium (Subcutaneous injection; 300-500 mg/kg; once daily; 5 d) treatment improves learning and memory in mice after surgery.

Cefazolin sodium (0-300 μg/ml; 6 or 24 h) has a direct anti-inflammatory effect on C8-B4 cells stimulated by lipopolysaccharide.Cefazolin sodium (0-400 μM; 72 h) treatment inhibits IL-2, IL-4 and IL-15-induced cell proliferation.Cefazolin sodium (0-400 μM; 30 min) treatment inhibits IL-2, IL-4, IL-15 and IL-21-stimulated JAK3 phosphorylation.Cell Viability Assay Cell Line:C8-B4 cells Concentration:0, 50, 100, 150, 200, 250, or 300 μg/ml Incubation Time:6 or 24 hours Result:Inhibited the increase of IL-1β at all doses, but inhibited the increase of IL-6 only at 200 μg/ml.Cell Proliferation Assay Cell Line:PBMC, and TF-1 cells Concentration:0, 100, 200, and 400 μM Incubation Time:72 hours Result:Reduced IL-2, IL-4 and IL-15-induced cell proliferation, suggested that Cefazolin interferes not only with IL-15Rα, but also with IL-2/IL-15Rβ and/or γc.Cell Viability Assay Cell Line:PBMC, NK-92, and TF-1 cells Concentration:0, 100, 200, and 400 μMIncubation Time:30 min Result:Diminished the phosphorylation of JAK3 in response to the cytokine treatment, concluded suppressing signal transduction by γc receptors.

Cefazolin sodium (Subcutaneous injection; 300-500 mg/kg; once daily; 5 d) treatment improves learning and memory in mice after surgery. Animal Model:6- to 8-week-old male CD-1 mice underwent clinical exploratory laparotomy Dosage:300-500 mg/kg Administration:Subcutaneous injection; 300-500 mg/kg; once daily; 5 days Result:Attenuated learning and memory dysfunction induced by the surgery.

NSC 291561 | SKF 41558

GPCR/G Protein

Antibacterial

PBPs| Peptidoglycan synthase| PON

Infection

——

27164-46-1

476.48

C14H13N8NaO4S3

>98% (HPLC)

DMSO: 10 mM

CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)[O-].[Na+]

——

(-20℃)

With Ice Pack

≥ 2 years